New Zealand
· Delayed Price · Currency is NZD Rua Bioscience Statistics
Total Valuation
Rua Bioscience has a market cap or net worth of NZD 4.91 million. The enterprise value is 4.16 million.
| Market Cap | 4.91M |
| Enterprise Value | 4.16M |
Important Dates
The next estimated earnings date is Monday, February 24, 2025.
| Earnings Date | Feb 24, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
Rua Bioscience has 163.72 million shares outstanding. The number of shares has increased by 2.95% in one year.
| Current Share Class | n/a |
| Shares Outstanding | 163.72M |
| Shares Change (YoY) | +2.95% |
| Shares Change (QoQ) | +1.26% |
| Owned by Insiders (%) | 33.41% |
| Owned by Institutions (%) | 2.44% |
| Float | 88.80M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 15.02 |
| PB Ratio | 0.71 |
| P/TBV Ratio | 1.07 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | -0.30 |
| EV / Sales | 13.16 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | -1.11 |
Financial Position
The company has a current ratio of 3.22, with a Debt / Equity ratio of 0.02.
| Current Ratio | 3.22 |
| Quick Ratio | 1.33 |
| Debt / Equity | 0.02 |
| Debt / EBITDA | n/a |
| Debt / FCF | -0.04 |
| Interest Coverage | -273.71 |
Financial Efficiency
Return on equity (ROE) is -102.05% and return on invested capital (ROIC) is -21.27%.
| Return on Equity (ROE) | -102.05% |
| Return on Assets (ROA) | -20.12% |
| Return on Capital (ROIC) | -21.27% |
| Revenue Per Employee | n/a |
| Profits Per Employee | n/a |
| Employee Count | n/a |
| Asset Turnover | 0.02 |
| Inventory Turnover | 0.56 |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -73.91% in the last 52 weeks.
| Beta (5Y) | n/a |
| 52-Week Price Change | -73.91% |
| 50-Day Moving Average | 0.03 |
| 200-Day Moving Average | 0.04 |
| Relative Strength Index (RSI) | 48.43 |
| Average Volume (20 Days) | 256,444 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Rua Bioscience had revenue of NZD 316,350 and -13.72 million in losses. Loss per share was -0.09.
| Revenue | 316,350 |
| Gross Profit | 112,207 |
| Operating Income | -4.62M |
| Pretax Income | -13.72M |
| Net Income | -13.72M |
| EBITDA | -4.28M |
| EBIT | -4.62M |
| Loss Per Share | -0.09 |
Balance Sheet
The company has 895,131 in cash and 147,780 in debt, giving a net cash position of 747,351 or 0.00 per share.
| Cash & Cash Equivalents | 895,131 |
| Total Debt | 147,780 |
| Net Cash | 747,351 |
| Net Cash Per Share | 0.00 |
| Equity (Book Value) | 6.77M |
| Book Value Per Share | 0.04 |
| Working Capital | 1.94M |
Cash Flow
In the last 12 months, operating cash flow was -3.74 million and capital expenditures -1,208, giving a free cash flow of -3.74 million.
| Operating Cash Flow | -3.74M |
| Capital Expenditures | -1,208 |
| Free Cash Flow | -3.74M |
| FCF Per Share | -0.02 |
Margins
| Gross Margin | 35.47% |
| Operating Margin | -1,459.98% |
| Pretax Margin | -4,336.57% |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
Rua Bioscience does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -2.95% |
| Shareholder Yield | -2.95% |
| Earnings Yield | -300.00% |
| FCF Yield | -76.10% |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
Rua Bioscience has an Altman Z-Score of 1.71. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | 1.71 |
| Piotroski F-Score | n/a |